scholarly journals Intravenous Immunoglobulin G Therapy in Streptococcal Toxic Shock Syndrome: A European Randomized, Double-Blind, Placebo-Controlled Trial

2003 ◽  
Vol 37 (3) ◽  
pp. 333-340 ◽  
Author(s):  
J. Darenberg ◽  
N. Ihendyane ◽  
J. Sjolin ◽  
E. Aufwerber ◽  
S. Haidl ◽  
...  
Keyword(s):  
Intravenous Immunoglobulin ◽  
Immunoglobulin G ◽  
Toxic Shock Syndrome ◽  
Controlled Trial ◽  
Streptococcal Toxic Shock Syndrome ◽  
Toxic Shock ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Intravenous Immunoglobulin G

Adjunctive Treatment of Streptococcal Toxic Shock Syndrome Using Intravenous Immunoglobulin: Case Report and Review

1997 ◽  
Vol 102 (1) ◽  
pp. 111-112 ◽  
Author(s):  
Carlos M Perez ◽  
Bernard M Kubak ◽  
Henry G Cryer ◽  
Saleh Salehmugodam ◽  
Paul Vespa ◽  
...  
Keyword(s):  
Case Report ◽  
Intravenous Immunoglobulin ◽  
Toxic Shock Syndrome ◽  
Adjunctive Treatment ◽  
Streptococcal Toxic Shock Syndrome ◽  
Toxic Shock

A controlled trial of intravenous immunoglobulin G in chronic fatigue syndrome

1990 ◽  
Vol 89 (5) ◽  
pp. 554-560 ◽  
Author(s):  
Phillip K. Peterson ◽  
Judy Shepard ◽  
Mark Macres ◽  
Carlos Schenck ◽  
John Crosson ◽  
...  
Keyword(s):  
Chronic Fatigue Syndrome ◽  
Intravenous Immunoglobulin ◽  
Immunoglobulin G ◽  
Controlled Trial ◽  
Chronic Fatigue ◽  
Fatigue Syndrome ◽  
Intravenous Immunoglobulin G

A double-blind, cross-over trial of intravenous immunoglobulin G in multiple sclerosis: Preliminary results

1997 ◽  
Vol 3 (2) ◽  
pp. 145-148 ◽  
Author(s):  
P. Soelberg Sørensen ◽  
B. Wanscher ◽  
K. Schreiber ◽  
M. Blinkenberg ◽  
C.V. Jensen ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Intravenous Immunoglobulin ◽  
Immunoglobulin G ◽  
Progressive Multiple Sclerosis ◽  
Ivig Treatment ◽  
Double Blind Study ◽  
Intravenous Methylprednisolone ◽  
Double Blind ◽  
Relapsing Remitting ◽  
Intravenous Immunoglobulin G

We enrolled 25 patients with relapsing-remitting or relapsing progressive multiple sclerosis (MS) in a randomized placebo-controlled double-blind study of intravenous immunoglobulin G (IVIG). IVIG Iglkg daily for 2 days was administered every 4 weeks for 24 weeks. Seventeen patients completed the whole trial, whereas eight patients discontinued the trial; four during IVIG treatment and four on placebo. Of the 17 patients who completed the trial, II had no exacerbations during IVIG treatment compared with only six on placebo (P=0.05). The total number of exacerbations in the IVIG period was I / and in the placebo period 15 (NS), and the number of severe exacerbations requiring treatment with intravenous methylprednisolone was four during treatment with IVIG and six on placebo (NS). The results suggest that IVIG treatment may be of beneft for prevention of exacerbations in patients with relapsing MS.

scholarly journals Correction: A Preliminary Randomized Double Blind Placebo-Controlled Trial of Intravenous Immunoglobulin for Japanese Encephalitis in Nepal

PLoS ONE ◽  
2015 ◽  
Vol 10 (8) ◽  
pp. e0136008
Author(s):  
Ajit Rayamajhi ◽  
Sam Nightingale ◽  
Nisha Keshary Bhatta ◽  
Rupa Singh ◽  
Elizabeth Ledger ◽  
...  
Keyword(s):  
Intravenous Immunoglobulin ◽  
Japanese Encephalitis ◽  
Controlled Trial ◽  
Double Blind ◽  
Double Blind Placebo

Early intravenous immunoglobulin therapy for group A β-haemolytic streptococcal meningitis with toxic shock syndrome

2021 ◽  
Vol 14 (3) ◽  
pp. e238472
Author(s):  
Derick Adigbli ◽  
Valerie Rozen ◽  
Archie Darbar ◽  
Pierre Janin
Keyword(s):  
Supportive Care ◽  
Intravenous Immunoglobulin ◽  
Toxic Shock Syndrome ◽  
Immunoglobulin Therapy ◽  
High Dose ◽  
Streptococcal Toxic Shock Syndrome ◽  
Full Time ◽  
Toxic Shock ◽  
Intravenous Immunoglobulin Therapy ◽  
Group A

A woman in her forties was transferred to a Sydney (Australia)-based tertiary hospital, following presentation to a regional hospital with group A Streptococcus (GAS) otomastoiditis; complicated by meningitis, venous sinus thrombosis, haemorrhagic cerebral infarction and subdural empyema. She rapidly deteriorated with profound cardiovascular collapse. Despite initiation of high dose vasoactive therapy, she remained shocked and developed multiorgan dysfunction syndrome. Early intravenous immunoglobulin therapy (140 g in two doses) was initiated as an adjunct to antimicrobial, surgical and supportive care for refractory streptococcal toxic shock syndrome. Over the course of a twelve-day intensive care unit stay she made good progress with de-escalation of her vasoactive supportive care and reversal of her organ injuries. She was subsequently discharged to ward-based care. At her three-month follow-up appointment she had significantly reduced neurological deficit. Five months following her presentation to hospital she had returned to full-time work.

Sign in / Sign up

Export Citation Format

Share Document